Pasar al contenido principal

ALTERACION EN LOS CIRCUITOS INHIBIDORES EN EL HIPOCAMPO EN EL SINDROME DE DOWN: UNA OPORTUNIDAD TERAPEUTICA

PID2022-141900OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO CENTRE DE REGULACIO GENOMICA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 31
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lamivudine modulates the expression of neurological impairment-related genes and LINE-1 retrotransposons in brain tissues of a Down syndrome mouse model

  • Borgognone, Alessandra|||0000-0001-5487-3016
  • Casadellà, Maria|||0000-0002-4115-2305
  • Martínez de Lagrán, María|||0000-0002-0836-6491
  • Paredes, Roger|||0000-0002-6553-691X
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Dierssen, Mara|||0000-0003-0853-6865
  • Elizalde-Torrent, Aleix|||0000-0001-7405-777X
Elevated activity of retrotransposons is increasingly recognized to be implicated in a wide range of neurodegenerative and neurodevelopmental diseases, including Down syndrome (DS), which is the most common chromosomal condition causing intellectual disability globally. Previous research by our group has revealed that treatment with lamivudine, a reverse transcriptase inhibitor, improved neurobehavioral phenotypes and completely rescued hippocampal-dependent recognition memory in a DS mouse model, Ts65Dn. We hypothesized that retrotransposition rates would increase in the Ts65Dn mouse model, and lamivudine could block retrotransposons. We analyzed the differentially expressed long interspersed element-1 (LINE-1 or L1) mapping on MMU16 and 17, and showed for the first time that retrotransposition could be associated with Ts65Dn's pathology, as misregulation of L1 was found in brain tissues associated with trisomy. In the cerebral cortex, 6 out of 26 upregulated L1s in trisomic treated mice were located in the telomeric region of MMU16 near Ttc3, Kcnj6, and Dscam genes. In the hippocampus, one upregulated L1 element in trisomic treated mice was located near the Fgd4 gene on MMU16. Moreover, two downregulated L1s rescued after treatment with lamivudine were located in the intronic region of Nrxn1 (MMU17) and Snhg14 (MMU7), implicated in a variety of neurodegenerative disorders. To gain further insight into the mechanism of this improvement, we here analyzed the gene expression profile in the hippocampus and cerebral cortex of trisomic mice treated and no-treated with lamivudine compared to their wild-type littermates. We found that treatment with lamivudine rescued the expression of 24% of trisomic genes in the cortex (located on mouse chromosome (MMU) 16 and 17) and 15% in the hippocampus (located in the human chromosome 21 orthologous regions), with important DS candidate genes such as App and Ets2, rescued in both regions.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Astrocytopathy is associated with CA1 synaptic dysfunction in a mouse model of Down syndrome

  • Fernández-Blanco, Álvaro
  • González-Arias, Candela
  • Sierra, Cesar
  • Zamora Moratalla, Alfonsa
  • Perea, Gertrudis
  • Dierssen, Mara
Brain pathophysiology in Down syndrome (DS), the most common genetic cause of intellectual disability, has traditionally been considered a consequence of neuronal dysfunction. However, although it is well documented that astrocytes play a critical role in brain homeostasis, synaptic regulation, and neuronal support, and their malfunction has been associated with the onset and progression of different neurological disorders, only a few studies have addressed whether astrocyte dysfunction can contribute to the DS pathophysiology. Astrocytes are increased in number and size, and show increased levels of expression of astroglial markers like S100ß and GFAP. In this study, we detected a region-specific increase in astrocyte population in CA1 and, to a lesser extent, in the dentate gyrus. Single-nucleus transcriptomic profiling identified markers associated with reactive astroglia, synaptic transmission, and neuroinflammation in trisomic astrocytes. Functional analysis revealed abnormal Ca2+ oscillations in trisomic astrocytes and impaired astrocyte-to-neuron communication in CA1, the most affected subregion, leading to astrocyte-mediated excitatory synaptic depression. Our findings demonstrate that astrocytes play an active and critical role in the pathophysiology of DS, not only as reactive responders to neuronal injury but as key contributors to the disease process itself. This astrocytic dysfunction presents a region-specific distribution within the hippocampus, suggesting localized vulnerability and complex glial involvement in DS-related neuropathology., The lab of MD is supported by the Secretaria d¿Universitats i Recerca del Departament d'Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926). We also acknowledge the support of the Agencia Estatal de Investigación (PID2022-141900OB-I00 INTO-DS funded by MICIU/AEI/10.13039/501100011033/FEDER, UE). This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 848077). The publication is part of the grant PRE2018-084504, funded by MCIN/AEI/10.13039/501100011033 and by the FSE+ (AFB). Additionally, we have been supported by Fundació La Marató TV3 (201620-31 and 225619), and by PID2022-142617NB-I00 and PID2019-106579RB-I00 funded by MCIN/AEI/10.13039/501100011033 to G.P.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Attitudes towards a multimodal precision medicine algorithm for predicting treatment response in depression: findings from a large cross-sectional European survey

  • Wahner, Viktor T. H.
  • Dierssen, Mara
  • Perera Bel, Júlia
  • Sanz, Ferran
  • Baune, Bernhard T.
Background: Precision medicine aims to facilitate a more individualized treatment selection and a more accurate diagnosis. While there is broad ranging research on precision psychiatry and the corresponding computational tools, its concepts and implementation are underway, little is known about the attitudes towards the actual use of precision psychiatry tools in the management of major psychiatric disorders, such as Major Depressive Disorder (MDD). This study aims to investigate the attitudes of depressive patients, professionals (physicians, psychologists and scientists) and the general population towards a novel, multimodal precision medicine algorithm designed to predict antidepressant treatment response. Methods: 5490 participants from 21 European countries, consisting of three groups of stakeholders, patients with depression (n= 421), professionals (n = 367) and the general population (n = 4702), were polled with a newly developed cross-sectional survey. A hypothetical decision scenario was used to examine the participants' attitudes, in which they were asked for their approval or disapproval for the application of a multimodal precision medicine algorithm to predict treatment response in antidepressant-treatment.3. Results: The general population had an acceptance rate of 78.8%. Overall, 74.6% of patients with MDD would agree to undergo testing using the multimodal algorithm in their current situation and 80.2% reported they would have done so at the time of their first diagnosis. In contrast, the psychiatrist's acceptance rates towards a multimodal algorithm were higher when patients had been in treatment for some time (79.3%) compared to those who had only recently been diagnosed (55.2%). This pattern was present across all other specialties within the professionals group. A considerable number of participants wished to receive more information before deciding, but few declined its application altogether. All groups indicated an openness towards personalized treatment options in general. Conclusion: Overall, participants indicated a large degree of acceptance towards the application of a multimodal precision medicine algorithm. Although limited by the hypothetical nature of the decision scenario, this study provides valuable perspectives from different stakeholders. Future research should move beyond attitudes and address further implementation hurdles that need to be overcome for the successful implementation of novel precision psychiatry approaches in psychiatric care., This study is part of the project "Toward PrecisiOn Medicine for the Prediction of Treatment response in major depressive disorder through stratification of combined clinical and -omics signatures", which is supported by the German Federal Ministry of Health (BMG) (2521FSB004_PROMPT), the National Centre for Research and Development Poland (NCBR) (PerMed/III/2/PROMPT/2021), the Italian Ministry of Health (IT-MoH) (ERP-2020-23671059), The French National Research Agency (ANR) (ANR-20-PERM-0003), the Health Department -Generalitat de Catalunya (DS-CAT) (SLD044/20/000001) and the Instituto de Salud Carlos III (ISCIII) (IHMC22/00026) under the frame of ERA PerMed. We acknowledge support of the Spanish Ministry of Science and Innovation (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033; PID2022-141900OB-I00), the Generalitat de Catalunya through the CERCA programme, the EMBL partnership and Fundació Marató TV3 (# 202212-30) to MD lab. The assistant research position of Giulia Perusi is funded by ERA-PerMed PROMPT project (IT-MoH ERP-2020-23671059). The Ph.D. student position of Valentina Menesello was partly funded by the PNRR -DM 117/2023 Grant. Massimo Gennarelli and Alessandra Minelli are supported by the Italian Ministry of Health (IT-MoH) under Grant Ricerca Corrente 2025 (RC-2025).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Modeling the impact of neuromorphological alterations in Down syndrome on fast neural oscillations

  • Clusella, Pau
  • Manubens-Gil, Linus, 1989-
  • García Ojalvo, Jordi
  • Dierssen, Mara
Cognitive disorders, including Down syndrome (DS), present significant morphological alterations in neuron architectural complexity. However, the relationship between neuromorphological alterations and impaired brain function is not fully understood. To address this gap, we propose a novel computational model that accounts for the observed cell deformations in DS. The model consists of a cross-sectional layer of the mouse motor cortex, composed of 3000 neurons. The network connectivity is obtained by accounting explicitly for two single-neuron morphological parameters: the mean dendritic tree radius and the spine density in excitatory pyramidal cells. We obtained these values by fitting reconstructed neuron data corresponding to three mouse models: wild-type (WT), transgenic (TgDyrk1A), and trisomic (Ts65Dn). Our findings reveal a dynamic interplay between pyramidal and fast-spiking interneurons leading to the emergence of gamma activity (∼40 Hz). In the DS models this gamma activity is diminished, corroborating experimental observations and validating our computational methodology. We further explore the impact of disrupted excitation-inhibition balance by mimicking the reduction recurrent inhibition present in DS. In this case, gamma power exhibits variable responses as a function of the external input to the network. Finally, we perform a numerical exploration of the morphological parameter space, unveiling the direct influence of each structural parameter on gamma frequency and power. Our research demonstrates a clear link between changes in morphology and the disruption of gamma oscillations in DS. This work underscores the potential of computational modeling to elucidate the relationship between neuron architecture and brain function, and ultimately improve our understanding of cognitive disorders., PC and JGO have received funding from the Future and Emerging Technologies Programme (FET) of the European Union’s Horizon 2020 research and innovation programme (project NEUROTWIN, grant agreement No 101017716). JGO was also financially supported by the Spanish Ministry of Science and Innovation (project reference PID2021-127311NB-I00), the FEDER funds of the Spanish State Research Agency (project reference MICIN/AEI/10.13039/501100011033/FEDER), the Maria de Maeztu Programme for Units of Excellence in R\&D of the Spanish State Research Agency (project reference CEX2018-000792-M), and by the ICREA Academia program. LMG was supported by the National Natural Science Foundation of China (RFIS-I grant, reference 32350410413). MD acknowledges financial support from the Spanish Ministry of Science and Innovation (projects CPP2022-009659 and RTC2019-007329-1), the Spanish State Research Agency (project INTO-DS, reference PID2022-141900OB-I00), the Marato-TV3 Foundation (202212-30-31-32), and the European Comission Horizon 2020 programme (projects H2020-899986 and GO-DS21-848077). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Factors influencing patient decision-making on a multimodal precision medicine algorithm for depression: a qualitative European multicentre study of the PROMPT consortium

  • Glaser, Rosa
  • Dierssen, Mara
  • Perera Bel, Júlia
  • Sanz, Ferran
  • Baune, Bernhard T.
Background: Precision medicine promises to improve treatment outcomes by tailoring interventions to patients' individual characteristics. However, the use of precision medicine tools requires patient acceptance, which remains underexplored. This qualitative study investigated factors influencing patient perspectives on a multimodal precision medicine algorithm to predict antidepressant response in patients suffering from Major Depressive Disorder (MDD). Methods: To explore patients' perspectives on the use of a multimodal algorithm, semi-structured focus groups were conducted with 44 patients diagnosed with moderate to severe depression across three European sites (Germany, Poland, Italy) in the PROMPT study. Discussions were transcribed and translated into English for analysis. A qualitative, structured content analysis approach was then used to analyse the data. Results: Patients' perspectives on using a multimodal algorithm in MDD revealed a complex interplay of decision-making factors: while perceived clinical benefits, such as a reduction in trial-and-error prescribing and reassurance, promoted acceptance of the algorithm, concerns about cost, waiting time and the emotional impact of unfavourable results tended to discourage acceptance. Patients' general beliefs about mental illness and its treatment shaped their attitudes toward the application of the algorithm. Many participants emphasised the importance of trust in physicians and preferred testing within the context of an established therapeutic relationship. Misconceptions about the algorithm's accuracy and capabilities, and fears of medical reductionism, were common. Conclusions: While patients are open to the use of a multimodal precision medicine algorithm for MDD, they emphasised the need for individualised, transparent communication and emotional support. The results highlight the importance of patient-centred communication strategies and guidelines for the ethical implementation of precision psychiatry., This study is part of the project "Toward PrecisiOn Medicine for the Prediction of Treatment response in major depressive disorder through stratification of combined clinical and -omics signatures", which is supported by the German Federal Ministry of Health (BMG) (2521FSB004_PROMPT), the National Centre for Research and Development Poland (NCBR) (PerMed/III/2/PROMPT/2021), the Italian Ministry of Health (IT-MoH) (ERP-2020-23671059), The French National Research Agency (ANR) (ANR-20-PERM-0003), the Health Department -Generalitat de Catalunya (DS-CAT) (SLD044/20/000001) and the Instituto de Salud Carlos III (ISCIII) (IHMC22/00026) under the frame of ERA PerMed. We acknowledge support of the Spanish Ministry of Science and Innovation (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033; PID2022-141900OB-I00), the Generalitat de Catalunya through the CERCA programme, the EMBL partnership and Fundació Marató TV3 (# 202212-30) to MD lab. MG and AM are supported by the Italian Ministry of Health (IT-MoH) under Grant Ricerca Corrente 2025 (RC-2025).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Methods for identifying epilepsy surgery targets using invasive EEG: a systematic review

  • Ivankovic, Karla
  • Principe, Alessandro
  • Zucca, Riccardo
  • Dierssen, Mara
  • Rocamora Zúñiga, Rodrigo Alberto
Background: The pre-surgical evaluation for drug-resistant epilepsy achieves seizure freedom in only 50-60% of patients. Efforts to identify quantitative intracranial EEG (qEEG) biomarkers of epileptogenicity are needed. This review summarizes and evaluates the design of qEEG studies, discusses barriers to biomarker adoption, and proposes refinements of qEEG study protocols. Methods: We included exploratory and prediction prognostic studies from MEDLINE and Scopus published between 2017 and 2023 that investigated qEEG markers for identifying the epileptogenic network as the surgical target. Cohort parameters, ground truth references, and analytical approaches were extracted. Results: Out of 1789 search results, 128 studies were included. The study designs were highly heterogeneous. Half of the studies included a non-consecutive cohort, with sample sizes ranging from 2 to 166 patients (median of 16). The most common minimum follow-up was one year, and the seizure onset zone was the most common ground truth. Prediction studies were heterogeneous in their analytical approaches, and only 25 studies validated the marker through post-surgical outcome prediction. Outcome prediction performance decreased in larger cohorts. Conversely, longer follow-up periods correlated with higher prediction accuracy, and connectivity-based approaches yielded better predictions. The data and code were available in only 9% of studies. Conclusions: To enhance the validation qEEG markers, we propose standardizing study designs to resemble clinical trials. This includes using a consecutive cohort with long-term follow-up, validating against surgical resection as ground truth, and evaluating markers through post-surgical outcome prediction. These considerations would improve the reliability and clinical adoption of qEEG markers., K.I. is supported by Ajuts Destinats a Universitats, centres de recerca i fundacions hospitalàries per contractar personal investigador novell per a l'any 2022 (FI-DGR Grant Number: 14802). A.P. is supported by Fundación Tatiana-Proyectos en Neurociencia (Grant 2022-1514). R.Z. is supported by Neurotech-EU (Grant agreement ID: 101035817). M.D. is funded by the Agencia Estatal de Investigación (PID2022-141900OB-I00 INTO-DS), H2020 European Union's Horizon 2020 research and innovation programme under grant agreement No. 848077 and 899986, Jerôme Lejeune Foundation #2002. The APC was funded by Fundación Tatiana¿Proyectos en Neurociencia (Grant 20.22-15.14).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Disease-specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease

  • Fructuoso, Marta
  • Vermeiren, Yannick
  • Boluda, Susana
  • Stimmer, Lev
  • Crans, René A. J.
  • Xicota Vila, Laura, 1987-
  • Eisel, Uli
  • Ortí Casañ, Natalia
  • Bun, Philippe
  • Duyckaerts, Charles
  • Delabar, Jean-Maurice
  • Strydom, Andre
  • Van Dam, Debby
  • Dierssen, Mara
  • De Deyn, Peter
  • Potier, Marie-Claude
Introduction: The locus coeruleus (LC), the brain's primary source of noradrenaline (NA), undergoes early neurodegeneration in Parkinson's disease (PD), Alzheimer's diseases (AD), and Down syndrome (DS); however, differences have not been examined in parallel. Methods: Post mortem brains (n = 67) from individuals with AD, DS-AD, and PD without and with dementia (PD-D) and controls were analyzed for amyloid beta (Aβ), phosphorylated tau (pTau), α-synuclein, endo-lysosomal alterations, biogenic amines, and selective biomarkers. Results: LC degeneration correlated with age, peaking in AD and PD-D, while NA and dopaminergic metabolites were significantly reduced only in PD-D. DS-AD, the youngest group, showed the highest Aβ and pTau levels but the least noradrenergic neuron loss. We demonstrated for the first time that endosomal alterations were present in AD, lysosomal changes were present in PD-D/DS-AD, and DYRK1A, a key protein from chromosome 21, was elevated only in DS-AD. Discussion: Loss of noradrenergic neurons may occur independently of amyloid and tau pathologies. Highlights: We provide the first analysis of neuropathological and biochemical features including biogenic amines of the LC in AD, DS, and PD. Loss of noradrenergic neurons was most severe in AD and PD. Only in DS, levels of DYRK1A - a kinase encoded on chromosome 21 and implicated in neurodegenerative processes - were elevated and negatively correlated to biogenic amine levels. Although individuals with DS having AD were the youngest group, they had the highest levels of amyloid and tau pathologies, but less noradrenergic neurons loss compared to other disease groups., The authors thank Jerome-Lejeune Fondation, which awarded M.F. and R.A.J.C. the Sisley d'Ornano-Lejeune postdoctoral fellowship 2019 and 2021, respectively. R.A.J.C. was also supported by the Sello de Excelencia ISCIII-HEALTH (IHMC22/00026). The authors thank Neuro-CEB (France), The Neurobiobank of the Institute Born-Bunge (NBB-IBB; FAGG registration ID BB190113) (Antwerp, Belgium), University of Groningen Brain Bank (the Netherlands), Institute of Psychiatry Kings College brain bank (UK), and Cambridge Brain Bank (UK) biobanks. The authors also thank Escourolle Laboratory of the Neuropathology Department of Pitié-Salpetrière Hospital in Paris (France). The authors gratefully acknowledge the Histomics core facility of ICM and the NeurImag Imaging core facility, part of the IPNP, Inserm 1266 unit and Université Paris Cité, part of the GIS IBISA and the national infrastructure France BioImaging supported by the National Research Agency (ANR-10-INBS-04). This study was supported by a grant from Joint Program Neurodegenerative Diseases Agence Nationale de la Recherche JPND ANR-17-JPCD-0003 HEROES (postdoctoral fellowship to M.F.), the Centre Of Excellence Neurodegenerative Diseases Agence Nationale de la Recherche COEN-0002 COEN-4024 and MRC MR/R024901/1, Institut National de la Santé et de la Recherche Médicale in collaboration with the Paris Brain Institute (ICM), Institut Hospitalo-Universitario-A ICM, and was supported with funding from the Investissement d'Avenir (ANR-10-AIHU-06)). Part of the experiments were funded by the Agencia Estatal de Investigación (PID2022-141900OB-I00 INTO-DS, AC170006 to, ZonMW Grant 733051072). The CIBER of Rare Diseases is an initiative of the ISCIII. The authors acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), the Generalitat de Catalunya through the CERCA program and to the EMBL partnership.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Understanding obesity in individuals with down syndrome: caregiver perceptions, awareness, and motivation

  • Cahill, Thomas
  • Nalesso, Valerie
  • Clarke, Pat
  • Martínez de Lagrán Cabredo, María
  • Strydom, Andre
  • Chan, Li
  • Potier, Marie-Claude
  • Beckers, Johannes
  • Langohr, Klaus
  • Liò, Pietro
  • Torre Fornell, Rafael de la
  • Forcano, Laura
  • Hiance-Delahaye, Anna
  • Herault, Yann
  • Dierssen, Mara
Background: Individuals with Down syndrome (DS) are at an increased risk of obesity and, subsequently, its cardiometabolic and cognitive impacts. Caregivers play a critical role in managing health, yet their perceptions and behaviors have been poorly characterized. Methods: We performed a cross-sectional online survey of caregivers (n = 764) taking care of 48% females and 52% males with DS, conducted across European populations, predominantly in Spain and France. We assessed perceived obesity, perceived harmfulness of current weight, professional consultation, and confidence in promoting healthy behaviors. Associations were examined using chi-square tests, correlation analysis, and ordinal and logistic regression models. Results: Around one-third (32%) of caregivers perceived their family member with DS with obesity. Perceived obesity changed with age and was more frequently reported in female family members with DS. Awareness of general metabolic risk factors was high among caregivers, but half of respondents were unaware that abdominal fat affects brain health. Consultation with healthcare professionals was uncommon (57% "Never/Rarely/Sometimes") even among those perceived with obesity. Conclusions: Caregivers demonstrate good general awareness about high energy food risks but limited knowledge of the link between obesity and brain health. Enhancing caregiver education and supporting behavioral change could promote healthier lifestyles in families with individuals with DS., This project received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 848077 (GO-DS21). The lab of M.D. and of RTF are recognized by the Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2023). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033), the Generalitat de Catalunya through the CERCA program and the EMBL partnership. KL received funding from PID2023-148033OB-C21 of the Ministerio de Ciencia, Innovación y Universidades (Spain; MICIU/AEI/10.13039/501100011033) and the European Regional development Fund (FEDER). LC received funding from Wellcome Trust grant (217543/Z/19/Z), and Barts Charity grant (G-002162). AS received funding from Medical Research Council grants (MR/S011277/1, MR/S005145/1, and MR/R024901/1) and the Jerome LeJeune Foundation. MD received funding from the Agencia Estatal de Investigación (PID2022-141900OB-I00 funded by MICIU/AEI/10.13039/501100011033/ERDF, EU), Fundació La Marató-TV3 (#202212-30), Ministerio de Ciencia Innovación y Universidades (RTC2019-007230-1, RTC2019-007329-1, and CPP2022-009659 funded by MCIN/AEI/10.13039/501100011033 and EU's 'NextGenerationEU'/PRTR'). The CIBER of Rare Diseases is an initiative of the ISCIII. RDT and LF research was supported by CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB06/03/0028), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A highly conserved neuronal microexon in DAAM1 controls actin dynamics, RHOA/ROCK signaling, and memory formation

  • Poliński, Patryk
  • Miret-Cuesta, Marta
  • Zamora Moratalla, Alfonsa
  • Mantica, Federica
  • Cantero Recasens, Gerard, 1984-
  • Viana, Carlotta
  • Sabariego Navarro, Miguel
  • Normanno, Davide
  • Iñiguez, Luis P.
  • Bonnal, Sophie
  • Gómez-Riera, Raúl
  • Fanlo-Ucar, Hugo
  • Yap, Dominic S.
  • Martínez de Lagrán Cabredo, María
  • Fernández-Blanco, Álvaro
  • Rodríguez-Marin, Cristina
  • Permanyer, Jon
  • Fölsz, Orsolya
  • Domínguez-Sala, Eduardo
  • Sierra, Cesar
  • Wojnacki, José
  • Musoles Lleo, Juan Luis
  • Cosma, Maria Pia
  • Muñoz López, Francisco José, 1964-
  • Dierssen, Mara
  • Irimia Martínez, Manuel
Actin cytoskeleton dynamics is essential for proper nervous system development and function. A conserved set of neuronal-specific microexons influences multiple aspects of neurobiology; however, their roles in regulating the actin cytoskeleton are unknown. Here, we study a microexon in DAAM1, a formin-homology-2 (FH2) domain protein involved in actin reorganization. Microexon inclusion extends the linker region of the DAAM1 FH2 domain, altering actin polymerization. Genomic deletion of the microexon leads to neuritogenesis defects and increased calcium influx in differentiated neurons. Mice with this deletion exhibit postsynaptic defects, fewer immature dendritic spines, impaired long-term potentiation, and deficits in memory formation. These phenotypes are associated with increased RHOA/ROCK signaling, which regulates actin-cytoskeleton dynamics, and are partially rescued by treatment with a ROCK inhibitor. This study highlights the role of a conserved neuronal microexon in regulating actin dynamics and cognitive functioning., The research has been funded by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (ERCCoG-LS2-101002275 to M.I.), Spanish Ministry of Science and Innovation (PID2020-115040GB-I00 to M.I., PID2022−141900OB-I00 to M.D., PID2020- 114080GB-I00 to M.P.C., PID2023-1497670B-I00 to F.J.M. and PID2022-138245NB-I00 to E.H), the European Union’s Horizon 2020 research and innovation program under grant agreements No 964342 to M.P.C., 721890 to P.P. and 848077 to A.Z.M., the National Institutes of Health (NIH) (1R01NS137222-01 to M.D.) and AGAUR grants from Secretaria d’Universitats i Recerca del Departament d’Empresa iConeixement de la Generalitat de Catalunya to M.I., M.D. and M.P.C.. CRG acknowledges support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033), and the Generalitat de Catalunya through the CERCA program. M.S.N. received an FPU fellowship (FPU19/04789) from Ministerio de Universidades. This research was in part supported by grants from the Simons Foundation and Canadian Institutes of Health Research to B.J.B., who also holds the University of Toronto Banbury Chair in Medical Research and the Canada Research Chair in RNA Biology and Genomics.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Neurodevelopmental disorders: 2024 update

  • Martínez de Lagrán Cabredo, María
  • Bascón-Cardozo, Karen
  • Dierssen, Mara
Neurodevelopmental disorders encompass a range of conditions such as intellectual disability, autism spectrum disorder, rare genetic disorders and developmental and epileptic encephalopathies, all manifesting during childhood. Over 1,500 genes involved in various signaling pathways, including numerous transcriptional regulators, spliceosome elements, chromatin-modifying complexes and de novo variants have been recognized for their substantial role in these disorders. Along with new machine learning tools applied to neuroimaging, these discoveries facilitate genetic diagnoses, providing critical insights into neuropathological mechanisms and aiding in prognosis, and precision medicine. Also, new findings underscore the importance of understanding genetic contributions beyond protein-coding genes and emphasize the role of RNA and non-coding DNA molecules but also new players, such as transposable elements, whose dysregulation generates gene function disruption, epigenetic alteration, and genomic instability. Finally, recent developments in analyzing neuroimaging now offer the possibility of characterizing neuronal cytoarchitecture in vivo, presenting a viable alternative to traditional post-mortem studies. With a recently launched digital atlas of human fetal brain development, these new approaches will allow answering complex biological questions about fetal origins of cognitive function in childhood. In this review, we present ten fascinating topics where major progress has been made in the last year., The lab of M.D. acknowledges financial support from the Spanish Ministry of Science and Innovation (projects CPP2022-009659 and RTC2019-007329-1), the Spanish State Research Agency (project INTO-DS, reference PID2022-141900OB-I00), the Marato-TV3 Foundation (202212-30-31-32), and the European Comission Horizon 2020 programme (projects H2020-899986 and GO-DS21-848077). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of ISCIII.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Beyond quiescent and active: Intermediate microglial transcriptomic states in a mouse model of down syndrome

  • Fernández Blanco, Álvaro
  • Sierra, Cesar
  • Tejido, Clara
  • Dierssen, Mara
Research on microglia in Down syndrome (DS) has shown that microglial activation, increased inflammatory gene expression, and oxidative stress occur at different ages in DS brains. However, most studies resulted in simplistic definitions of microglia as quiescent or active, ignoring potential intermediate states. Indeed, recent work on microglial cells in young DS brains indicated that those evolve through different intermediate activation phenotypes before reaching a fully activated state. Here we used single nucleus RNA sequencing, to examine how trisomy affects microglial states in the Ts65Dn mouse model of DS. Despite no substantial changes in the proportion of glial populations, differential expression analysis revealed cell type-specific gene expression changes, most notably in astroglia, microglia, and oligodendroglia. Focusing on microglia, we identified differential expression of genes associated with different microglial states, including disease-associated microglia (DAMs), activated response microglia (ARMs), and human Alzheimer's disease microglia (HAMs), in trisomic microglia. Furthermore, pseudotime analysis reveals a unique reactivity profile in Ts65Dn microglia, with fewer in a homeostatic state and more in an intermediate aberrantly reactive state than in euploid microglia. This comprehensive understanding of microglial transcriptional dynamics sheds light on potential pathogenetic mechanisms but also possible avenues for therapy for neurodevelopmental disorders., The lab of MD is recognized by the Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2023). This project has received funding from the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033; PID2022-141900OB-I00 INTO-DS), from the European Union’s Horizon 2020 research and innovation program under grant agreement No 848077 and 899986, Jerôme Lejeune Foundation #2002, Fundació La Marató-TV3 (#2016/20-30), JPND Heroes Ministerio de Ciencia Innovación y Universidades (RTC2019-007230-1, RTC2019-007329-1; and CPP2022-009659). The CIBER of Rare Diseases is an initiative of the ISCIII. C.S. received the FI grant from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) de la Generalitat de Catalunya, and A.F.B. received an FPI-SO fellowship (PRE2018-084504).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A multimodal lifestyle intervention complemented with epigallocatechin gallate to prevent cognitive decline in APOE- ɛ4 carriers with Subjective Cognitive Decline: a randomized, double-blinded clinical trial (PENSA study)

  • Forcano, Laura
  • Soldevila-Domenech, Natalia
  • Boronat Rigol, Anna, 1990-
  • Sánchez Benavides, Gonzalo
  • Puig-Pijoan, Albert
  • Lorenzo, Thais
  • Aldea-Perona, Ana
  • Suárez-Calvet, Marc
  • Cuenca Royo, Aida Ma, 1981-
  • Gispert, Juan Domingo
  • Gomis González, Maria, 1988-
  • Minguillón, Carolina
  • Diaz-Pellicer, Patricia
  • Piera, Iris
  • Langohr, Klaus
  • Dierssen, Mara
  • Pizarro Lozano, Ma. Nieves
  • Mur-Gimeno E.
  • Grau, Oriol (Grau Rivera)
  • Molinuevo, José Luis
  • Torre Fornell, Rafael de la
  • PENSA working group
Background: The potential of dietary compounds to enhance the effects of multimodal lifestyle interventions (MLIs) on cognition in individuals at high risk of cognitive impairment remains unclear. Objectives: To assess whether the addition of a green tea extract enriched with epigallocatechin-3-gallate (EGCG) enhances the effects of an MLI. Design: Double-blind, randomized, two-arm, and placebo-controlled trial. Exploratory comparisons were made with a non-randomized group (NRG) receiving healthy lifestyle recommendations. Setting: Population-based study conducted in Barcelona, Spain PARTICIPANTS: APOE-ɛ4 carriers aged 60-80 with subjective cognitive decline INTERVENTION: A 12-month intensive MLI including dietary counseling, guided physical activity, and cognitive stimulation, combined with EGCG (5-6 mg/kg) or placebo, followed by a 3-month washout. Measurements: Primary endpoint was change in the modified Preclinical Alzheimer Cognitive Composite (PACC-exe) score. Results: 129 participants (65.1% 84 women, aged 66.7±5.5 years) were enrolled (52 MLI+EGCG, 52 MLI+placebo and 25 NRG), with126 (97.7%) included in the modified intention-to-treat analysis. After 12 months, no statistically significant difference was observed between MLI+EGCG and MLI+placebo in the PACC-exe (adjusted mean difference [AMD]: 0.12; 95%CI: -0.01, 0.24; p=0.061). However, participants in the MLI+EGCG group were 2.6 times more likely to show a reliable cognitive improvement. In exploratory analyses following a 3-month washout, the MLI+EGCG group showed significant cognitive benefits compared to the MLI+placebo (AMD: 0.19; 95%CI: 0.06, 0.32; p=0.005). Exploratory comparisons with the NRG also suggested greater gains in cognition and dementia risk reduction in both MLI groups, particularly with EGCG. Conclusions: While the primary outcome was not met, this proof-of-concept trial suggests that combining MLIs with EGCG warrants further investigation in larger, confirmatory studies., This study was mainly funded by the Alzheimer¿s Association, The PART THE CLOUD to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer's disease Program, grant 18PTC-R-592192 and Project PI17/00223, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by European Regional Development Fund (FEDER). RdlT leads the Consolidated "Clinical Research Group in Pharmacology and Development of Biomarkers and New Drugs", supported by the Generalitat de Catalunya (2021 SGR 00253 and 2021 SGR 01421). This research was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB06/03/0028), Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades (PID2022-141900OB-I00; PID2023-148033OB-C21) and Unión Europea - FEDER Fund; Grant AC22/00004 funded by Instituto de Salud Carlos III, and by the European Union NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MultiMemo, JPND program); and by the "Responsible Research and Innovation Awards" (RRI20/00005) organized by the ISCIII and promoted within the framework of the European project ORION (Open Responsible research and Innovation to further Outstanding kNowledge). NS-D had a predoctoral fellowship (2022 FI_B1 00026) from AGAUR-Generalitat de Catalunya, and TL had a predoctoral fellowship FI18/00041 from the ISCIII. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication., This study was mainly funded by the Alzheimer’s Association, The PART THE CLOUD to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer’s disease Program, grant 18PTC-R-592192 and Project PI17/00223, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by European Regional Development Fund (FEDER). RdlT leads the Consolidated “Clinical Research Group in Pharmacology and Development of Biomarkers and New Drugs”, supported by the Generalitat de Catalunya (2021 SGR 00253 and 2021 SGR 01421). This research was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB06/03/0028), Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades (PID2022-141900OB-I00; PID2023-148033OB-C21) and Unión Europea – FEDER Fund; Grant AC22/00004 funded by Instituto de Salud Carlos III, and by the European Union NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MultiMemo, JPND program); and by the "Responsible Research and Innovation Awards" (RRI20/00005) organized by the ISCIII and promoted within the framework of the European project ORION (Open Responsible research and Innovation to further Outstanding kNowledge). NS-D had a predoctoral fellowship (2022 FI_B1 00026) from AGAUR-Generalitat de Catalunya, and TL had a predoctoral fellowship FI18/00041 from the ISCIII. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deficits in neuronal architecture but not over-inhibition are main determinants of reduced neuronal network activity in a mouse model of overexpression of Dyrk1A

  • Manubens-Gil, Linus
  • Pons-Espinal, Meritxell
  • Gener, Thomas
  • Ballesteros-Yañez, Inmaculada
  • Martínez de Lagrán, María
  • Dierssen, Mara
In this study, we investigated the impact of Dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) overexpression, a gene associated with Down syndrome, on hippocampal neuronal deficits in mice. Our findings revealed that mice overexpressing Dyrk1A (TgDyrk1A; TG) exhibited impaired hippocampal recognition memory, disrupted excitation-inhibition balance, and deficits in long-term potentiation (LTP). Specifically, we observed layer-specific deficits in dendritic arborization of TG CA1 pyramidal neurons in the stratum radiatum. Through computational modeling, we determined that these alterations resulted in reduced storage capacity and compromised integration of inputs, with decreased high γ oscillations. Contrary to prevailing assumptions, our model suggests that deficits in neuronal architecture, rather than over-inhibition, primarily contribute to the reduced network. We explored the potential of environmental enrichment (EE) as a therapeutic intervention and found that it normalized the excitation-inhibition balance, restored LTP, and improved short-term recognition memory. Interestingly, we observed transient significant dendritic remodeling, leading to recovered high γ. However, these effects were not sustained after EE discontinuation. Based on our findings, we conclude that Dyrk1A overexpression-induced layer-specific neuromorphological disturbances impair the encoding of place and temporal context. These findings contribute to our understanding of the underlying mechanisms of Dyrk1A-related hippocampal deficits and highlight the challenges associated with long-term therapeutic interventions for cognitive impairments., We acknowledge support of the Spanish Ministry of Economy and Competitiveness (MINECO), “Centro de Excelencia Severo Ochoa 2013-2017”, SEV-2012-0208. The research leading to these results has received funding from MINECO (SAF2013-49129-C2-1-R; PID2022-141900OB-I00 and PID2019-110755RB-I00/AEI/10.13039/501100011033), H2020 SC1 Gene overdosage and comorbidities during the early lifetime in DS GO-DS21-848077, Jerôme Lejeune Foundation #2002, the NIH grant R01 EB028159 We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa ((CEX2020-001049-S, MCIN/AEI/10.13039/501100011033)) and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases is an initiative of the ISCIII., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001049-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A highly conserved neuronal microexon in DAAM1 controls actin dynamics, RHOA/ROCK signaling, and memory formation

  • Poliński, Patryk
  • Miret Cuesta, Marta
  • Zamora-Moratalla, Alfonsa
  • Mantica, Federica
  • Cantero-Recasens, Gerard
  • Viana, Carlotta
  • Sabariego-Navarro, Miguel
  • Normanno, Davide
  • Iñiguez, Luis P.
  • Morenilla-Palao, Cruz
  • Ordoño, Patricia
  • Bonnal, Sophie
  • Ellis, Jonathan D.
  • Gómez-Riera, Raúl
  • Fanlo-Ucar, Hugo
  • Yap, Dominic S.
  • Martínez de Lagrán, María
  • Fernández Blanco, Álvaro
  • Rodríguez Marín, Cristina
  • Permanyer, Jon
  • Fölsz, Orsolya
  • Domínguez-Sala, Eduardo
  • Sierra, César
  • Legutko, Diana
  • Wojnacki, José
  • Musoles Lleo, Juan Luis
  • Cosma, María Pía
  • Muñoz, Francisco José
  • Blencowe, Benjamín J.
  • Herrera, Eloisa
  • Dierssen, Mara
  • Irimia, Manuel
Actin cytoskeleton dynamics is essential for proper nervous system development and function. A conserved set of neuronal-specific microexons influences multiple aspects of neurobiology; however, their roles in regulating the actin cytoskeleton are unknown. Here, we study a microexon in DAAM1, a formin-homology-2 (FH2) domain protein involved in actin reorganization. Microexon inclusion extends the linker region of the DAAM1 FH2 domain, altering actin polymerization. Genomic deletion of the microexon leads to neuritogenesis defects and increased calcium influx in differentiated neurons. Mice with this deletion exhibit postsynaptic defects, fewer immature dendritic spines, impaired long-term potentiation, and deficits in memory formation. These phenotypes are associated with increased RHOA/ROCK signaling, which regulates actin-cytoskeleton dynamics, and are partially rescued by treatment with a ROCK inhibitor. This study highlights the role of a conserved neuronal microexon in regulating actin dynamics and cognitive functioning., We thank Kyung-Min Noh for providing the mESC line, Miguel Valverde and Francisco Muñoz for their help and feedback with the calcium imaging experiments, and members of the Irimia and Dierssen groups for constant scientific discussion and feedback. We also thank the CRG Genomics, Protein Technologies, Tissue Engineering and Advanced Light Microscopy Units for the RNA sequencing, protein purification, blastocyst injection and microscopy services, respectively. The research has been funded by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (ERCCoG-LS2-101002275 to M.I.), Spanish Ministry of Science and Innovation (PID2020-115040GB-I00 to M.I., PID2022−141900OB-I00 to M.D., PID2020- 114080GB-I00 to M.P.C., PID2023-1497670B-I00 to F.J.M. and PID2022-138245NB-I00 to E.H), the European Union’s Horizon 2020 research and innovation program under grant agreements No 964342 to M.P.C., 721890 to P.P. and 848077 to A.Z.M., the National Institutes of Health (NIH) (1R01NS137222-01 to M.D.) and AGAUR grants from Secretaria d’Universitats i Recerca del Departament d’Empresa iConeixement de la Generalitat de Catalunya to M.I., M.D. and M.P.C.. CRG acknowledges support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033), and the Generalitat de Catalunya through the CERCA program. M.S.N. received an FPU fellowship (FPU19/04789) from Ministerio de Universidades. This research was in part supported by grants from the Simons Foundation and Canadian Institutes of Health Research to B.J.B., who also holds the University of Toronto Banbury Chair in Medical Research and the Canada Research Chair in RNA Biology and Genomics., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001049-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Astrocytopathy Is Associated with CA1 Synaptic Dysfunction in a Mouse Model of Down Syndrome

  • Fernández-Blanco, Álvaro
  • González-Arias, Candela
  • Sierra, César
  • Zamora-Moratalla, Alfonsa
  • Perea, Gertrudis
  • Dierssen, Mara
This article belongs to the Special Issue Cellular and Molecular Alterations in the Down Syndrome Brain: A Starting Point for the Design of Therapeutic Approaches., Brain pathophysiology in Down syndrome (DS), the most common genetic cause of intellectual disability, has traditionally been considered a consequence of neuronal dysfunction. However, although it is well documented that astrocytes play a critical role in brain homeostasis, synaptic regulation, and neuronal support, and their malfunction has been associated with the onset and progression of different neurological disorders, only a few studies have addressed whether astrocyte dysfunction can contribute to the DS pathophysiology. Astrocytes are increased in number and size, and show increased levels of expression of astroglial markers like S100β and GFAP. In this study, we detected a region-specific increase in astrocyte population in CA1 and, to a lesser extent, in the dentate gyrus. Single-nucleus transcriptomic profiling identified markers associated with reactive astroglia, synaptic transmission, and neuroinflammation in trisomic astrocytes. Functional analysis revealed abnormal Ca2+ oscillations in trisomic astrocytes and impaired astrocyte-to-neuron communication in CA1, the most affected subregion, leading to astrocyte-mediated excitatory synaptic depression. Our findings demonstrate that astrocytes play an active and critical role in the pathophysiology of DS, not only as reactive responders to neuronal injury but as key contributors to the disease process itself. This astrocytic dysfunction presents a region-specific distribution within the hippocampus, suggesting localized vulnerability and complex glial involvement in DS-related neuropathology., The lab of MD is supported by the Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926). We also acknowledge the support of the Agencia Estatal de Investigación (PID2022-141900OB-I00 INTO-DS funded by MICIU/AEI/10.13039/501100011033/FEDER, UE). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848077). The publication is part of the grant PRE2018-084504, funded by MCIN/AEI/10.13039/501100011033 and by the FSE+ (AFB). Additionally, we have been supported by Fundació La Marató TV3 (201620-31 and 225619), and by PID2022-142617NB-I00 and PID2019-106579RB-I00 funded by MCIN/AEI/10.13039/501100011033 to G.P., Peer reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Caregiver-Associated Physical Activity Patterns, Dietary Behaviors and Interventional Beliefs in Individuals with Down Syndrome: Insights from a Large European Survey

  • Cahill, Thomas
  • Nalesso, Valerie
  • Clarke, Pat
  • Martínez de Lagrán, María
  • Strydom, André
  • Chan, Li
  • Potier, Marie-Claude
  • Beckers, Johannes
  • Langohr, Klaus|||0000-0001-7075-9192
  • Lio, Pietro
  • De la Torre Fornell, Rafael
  • Forcano, Laura
  • Hiance Delahaye, Anne
  • Herault, Yann
  • Dierssen, Mara
Background: Lifestyle factors such as diet and physical activity significantly impact on the risk of obesity in individuals with Down syndrome (DS). However, in the absence of national nutritional guidelines in individuals with DS, further work is needed to understand their dietary and physical activity patterns. In this work we retrieved caregivers’ responses on those aspects. Methods: We analyzed data from a cross-sectional online survey of caregivers of individuals with DS conducted as part of the GO-DS21 project and reported in the accompanying paper (nutrients-4216283) (n = 764). We explored physical activity patterns, dietary habits, beliefs around weight-loss interventions and caregiver confidence that family members with DS would engage in a healthier lifestyle. Associations were examined using correlation analysis, and cumulative and binary logistic regression models. Results: Caregivers reported that most individuals with DS exercised 1–3 times per week, with frequency declining with age. Males were more likely to exercise daily than females. Caregiver exercise frequency was positively correlated with that of their DS family member (¿ = 0.521, p < 0.001), suggesting clustering of shared health behaviors within households. In adjusted models, caregivers who exercised regularly had up to thirteen-fold higher odds of having a physically active family member with DS (aOR = 13.02, 95% CI: 7.40–24.06, p < 0.001). Fried food consumption and higher snack frequency were independently associated with perceived obesity status, while sugar-sweetened beverage consumption was not. Caregivers favored exercise as a weight-loss strategy, while anti-obesity drugs were endorsed by only 11% of caregivers primarily and were more likely to be endorsed when obesity was perceived (aOR = 4.21, 95% CI: 2.44–7.39, p < 0.001). Finally, caregiver confidence that their family member with DS would engage in healthier behaviors was associated with perceived obesity status and strongly associated with higher physical activity levels (aOR 14.68, 95% CI: 6.59–33.40, p < 0.001). Conclusions: In this large European caregiver survey, reported consumption of selected energy-dense foods was generally low, although fried food intake and higher snack frequency were associated with perceived obesity. Physical activity patterns were closely aligned between caregivers and individuals with DS, suggesting shared household health behaviors. These findings highlight the importance of involving caregivers and family environments in lifestyle interventions aimed at supporting physical activity and weight management in individuals with DS., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Understanding obesity in Individuals with Down syndrome: caregiver perceptions, awareness, and motivation

  • Cahill, Thomas
  • Nalesso, Valerie
  • Clarke, Pat
  • Martínez de Lagran, María
  • Strydom, André
  • Chan, Li
  • Potier, Marie-Claude
  • Beckers, Johannes
  • Langohr, Klaus|||0000-0001-7075-9192
  • Lio, Pietro
  • De la Torre Fornell, Rafael
  • Forcano, Laura
  • Hiance Delahaye, Anne
  • Herault, Yann
  • Dierssen, Mara
  • Consortium, GO-DS21
Background: Individuals with Down syndrome (DS) are at an increased risk of obesity and, subsequently, its cardiometabolic and cognitive impacts. Caregivers play a critical role in managing health, yet their perceptions and behaviors have been poorly characterized. Methods: We performed a cross-sectional online survey of caregivers (n = 764) taking care of 48% females and 52% males with DS, conducted across European populations, predominantly in Spain and France. We assessed perceived obesity, perceived harmful- ness of current weight, professional consultation, and confidence in promoting healthy behaviors. Associations were examined using chi-square tests, correlation analysis, and ordinal and logistic regression models. Results: Around one-third (32%) of caregivers perceived their family member with DS with obesity. Perceived obesity changed with age and was more frequently reported in female family members with DS. Awareness of general metabolic risk factors was high among caregivers, but half of respondents were unaware that abdominal fat affects brain health. Consultation with healthcare professionals was uncommon (57% “Never/Rarely/Sometimes”) even among those perceived with obesity. Conclusions: Caregivers demonstrate good general awareness about high energy food risks but limited knowledge of the link between obesity and brain health. Enhancing caregiver education and supporting behavioral change could promote healthier lifestyles in families with individuals with DS., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

A multimodal lifestyle intervention complemented with epigallocatechin gallate to prevent cognitive decline in APOE- e4 carriers with Subjective Cognitive Decline: a randomized, double-blinded clinical trial (PENSA study)

  • Forcano, Laura
  • Soldevila Domènech, Natàlia
  • Boronat Rigol, Anna
  • Sánchez Benavides, Gonzalo
  • Suárez Calvet, Marc
  • Cuenca, Aída
  • Domingo Gispert, Juan
  • Minguillón Gil, Carolina
  • Díaz Pellicer, Patricia
  • Fauria, Karine
  • Langohr, Klaus|||0000-0001-7075-9192
  • Dierssen, Mara
  • Grau Rivera, Oriol
  • Molinuevo Guix, José Luis
  • De la Torre Fornell, Rafael
Background The potential of dietary compounds to enhance the effects of multimodal lifestyle interventions (MLIs) on cognition in individuals at high risk of cognitive impairment remains unclear. Objectives To assess whether the addition of a green tea extract enriched with epigallocatechin-3-gallate (EGCG) enhances the effects of an MLI. Design Double-blind, randomized, two-arm, and placebo-controlled trial. Exploratory comparisons were made with a non-randomized group (NRG) receiving healthy lifestyle recommendations. Setting: Population-based study conducted in Barcelona, Spain Participants APOE-¿4 carriers aged 60-80 with subjective cognitive decline Intervention A 12-month intensive MLI including dietary counseling, guided physical activity, and cognitive stimulation, combined with EGCG (5-6 mg/kg) or placebo, followed by a 3-month washout. Measurements Primary endpoint was change in the modified Preclinical Alzheimer Cognitive Composite (PACC-exe) score. Results 129 participants (65.1% 84 women, aged 66.7±5.5 years) were enrolled (52 MLI+EGCG, 52 MLI+placebo and 25 NRG), with126 (97.7%) included in the modified intention-to-treat analysis. After 12 months, no statistically significant difference was observed between MLI+EGCG and MLI+placebo in the PACC-exe (adjusted mean difference [AMD]: 0.12; 95%CI: -0.01, 0.24; p=0.061). However, participants in the MLI+EGCG group were 2.6 times more likely to show a reliable cognitive improvement. In exploratory analyses following a 3-month washout, the MLI+EGCG group showed significant cognitive benefits compared to the MLI+placebo (AMD: 0.19; 95%CI: 0.06, 0.32; p=0.005). Exploratory comparisons with the NRG also suggested greater gains in cognition and dementia risk reduction in both MLI groups, particularly with EGCG. Conclusions While the primary outcome was not met, this proof-of-concept trial suggests that combining MLIs with EGCG warrants further investigation in larger, confirmatory studies., This study was mainly funded by the Alzheimer’s Association, The PART THE CLOUD to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer’s disease Program, grant 18PTC-R-592192 and Project PI17/00223, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by European Regional Development Fund (FEDER). RdlT leads the Consolidated “Clinical Research Group in Pharmacology and Development of Biomarkers and New Drugs”, supported by the Generalitat de Catalunya (2021 SGR 00253 and 2021 SGR 01421). This research was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB06/03/0028), Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades (PID2022-141900OB-I00; PID2023-148033OB-C21) and Unión Europea – FEDER Fund; Grant AC22/00004 funded by Instituto de Salud Carlos III, and by the European Union NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MultiMemo, JPND program); and by the "Responsible Research and Innovation Awards" (RRI20/00005) organized by the ISCIII and promoted within the framework of the European project ORION (Open Responsible research and Innovation to further Outstanding kNowledge). NS-D had a predoctoral fellowship (2022 FI_B1 00026) from AGAUR-Generalitat de Catalunya, and TL had a predoctoral fellowship FI18/00041 from the ISCIII. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication, Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A highly conserved neuronal microexon in DAAM1 controls actin dynamics, RHOA/ROCK signaling, and memory formation

  • Poliński, Patryk
  • Miret-Cuesta, Marta
  • Zamora Moratalla, Alfonsa
  • Mantica, Federica
  • Cantero Recasens, Gerard, 1984-
  • Viana, Carlotta
  • Sabariego Navarro, Miguel
  • Normanno, Davide
  • Iñiguez, Luis P.
  • Bonnal, Sophie
  • Gómez-Riera, Raúl
  • Fanlo-Ucar, Hugo
  • Yap, Dominic S.
  • Martínez de Lagrán Cabredo, María
  • Fernández-Blanco, Álvaro
  • Rodríguez-Marin, Cristina
  • Permanyer, Jon
  • Fölsz, Orsolya
  • Domínguez-Sala, Eduardo
  • Sierra, Cesar
  • Wojnacki, José
  • Musoles Lleo, Juan Luis
  • Cosma, Maria Pia
  • Muñoz López, Francisco José, 1964-
  • Dierssen, Mara
  • Irimia Martínez, Manuel
Actin cytoskeleton dynamics is essential for proper nervous system development and function. A conserved set of neuronal-specific microexons influences multiple aspects of neurobiology; however, their roles in regulating the actin cytoskeleton are unknown. Here, we study a microexon in DAAM1, a formin-homology-2 (FH2) domain protein involved in actin reorganization. Microexon inclusion extends the linker region of the DAAM1 FH2 domain, altering actin polymerization. Genomic deletion of the microexon leads to neuritogenesis defects and increased calcium influx in differentiated neurons. Mice with this deletion exhibit postsynaptic defects, fewer immature dendritic spines, impaired long-term potentiation, and deficits in memory formation. These phenotypes are associated with increased RHOA/ROCK signaling, which regulates actin-cytoskeleton dynamics, and are partially rescued by treatment with a ROCK inhibitor. This study highlights the role of a conserved neuronal microexon in regulating actin dynamics and cognitive functioning., The research has been funded by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (ERCCoG-LS2-101002275 to M.I.), Spanish Ministry of Science and Innovation (PID2020-115040GB-I00 to M.I., PID2022−141900OB-I00 to M.D., PID2020- 114080GB-I00 to M.P.C., PID2023-1497670B-I00 to F.J.M. and PID2022-138245NB-I00 to E.H), the European Union’s Horizon 2020 research and innovation program under grant agreements No 964342 to M.P.C., 721890 to P.P. and 848077 to A.Z.M., the National Institutes of Health (NIH) (1R01NS137222-01 to M.D.) and AGAUR grants from Secretaria d’Universitats i Recerca del Departament d’Empresa iConeixement de la Generalitat de Catalunya to M.I., M.D. and M.P.C.. CRG acknowledges support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033), and the Generalitat de Catalunya through the CERCA program. M.S.N. received an FPU fellowship (FPU19/04789) from Ministerio de Universidades. This research was in part supported by grants from the Simons Foundation and Canadian Institutes of Health Research to B.J.B., who also holds the University of Toronto Banbury Chair in Medical Research and the Canada Research Chair in RNA Biology and Genomics.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Disease-specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease

  • Fructuoso, Marta
  • Vermeiren, Yannick
  • Boluda, Susana
  • Stimmer, Lev
  • Crans, René A. J.
  • Xicota Vila, Laura, 1987-
  • Eisel, Uli
  • Ortí Casañ, Natalia
  • Bun, Philippe
  • Duyckaerts, Charles
  • Delabar, Jean-Maurice
  • Strydom, Andre
  • Van Dam, Debby
  • Dierssen, Mara
  • De Deyn, Peter
  • Potier, Marie-Claude
Introduction: The locus coeruleus (LC), the brain's primary source of noradrenaline (NA), undergoes early neurodegeneration in Parkinson's disease (PD), Alzheimer's diseases (AD), and Down syndrome (DS); however, differences have not been examined in parallel. Methods: Post mortem brains (n = 67) from individuals with AD, DS-AD, and PD without and with dementia (PD-D) and controls were analyzed for amyloid beta (Aβ), phosphorylated tau (pTau), α-synuclein, endo-lysosomal alterations, biogenic amines, and selective biomarkers. Results: LC degeneration correlated with age, peaking in AD and PD-D, while NA and dopaminergic metabolites were significantly reduced only in PD-D. DS-AD, the youngest group, showed the highest Aβ and pTau levels but the least noradrenergic neuron loss. We demonstrated for the first time that endosomal alterations were present in AD, lysosomal changes were present in PD-D/DS-AD, and DYRK1A, a key protein from chromosome 21, was elevated only in DS-AD. Discussion: Loss of noradrenergic neurons may occur independently of amyloid and tau pathologies. Highlights: We provide the first analysis of neuropathological and biochemical features including biogenic amines of the LC in AD, DS, and PD. Loss of noradrenergic neurons was most severe in AD and PD. Only in DS, levels of DYRK1A - a kinase encoded on chromosome 21 and implicated in neurodegenerative processes - were elevated and negatively correlated to biogenic amine levels. Although individuals with DS having AD were the youngest group, they had the highest levels of amyloid and tau pathologies, but less noradrenergic neurons loss compared to other disease groups., The authors thank Jerome-Lejeune Fondation, which awarded M.F. and R.A.J.C. the Sisley d'Ornano-Lejeune postdoctoral fellowship 2019 and 2021, respectively. R.A.J.C. was also supported by the Sello de Excelencia ISCIII-HEALTH (IHMC22/00026). The authors thank Neuro-CEB (France), The Neurobiobank of the Institute Born-Bunge (NBB-IBB; FAGG registration ID BB190113) (Antwerp, Belgium), University of Groningen Brain Bank (the Netherlands), Institute of Psychiatry Kings College brain bank (UK), and Cambridge Brain Bank (UK) biobanks. The authors also thank Escourolle Laboratory of the Neuropathology Department of Pitié-Salpetrière Hospital in Paris (France). The authors gratefully acknowledge the Histomics core facility of ICM and the NeurImag Imaging core facility, part of the IPNP, Inserm 1266 unit and Université Paris Cité, part of the GIS IBISA and the national infrastructure France BioImaging supported by the National Research Agency (ANR-10-INBS-04). This study was supported by a grant from Joint Program Neurodegenerative Diseases Agence Nationale de la Recherche JPND ANR-17-JPCD-0003 HEROES (postdoctoral fellowship to M.F.), the Centre Of Excellence Neurodegenerative Diseases Agence Nationale de la Recherche COEN-0002 COEN-4024 and MRC MR/R024901/1, Institut National de la Santé et de la Recherche Médicale in collaboration with the Paris Brain Institute (ICM), Institut Hospitalo-Universitario-A ICM, and was supported with funding from the Investissement d'Avenir (ANR-10-AIHU-06)). Part of the experiments were funded by the Agencia Estatal de Investigación (PID2022-141900OB-I00 INTO-DS, AC170006 to, ZonMW Grant 733051072). The CIBER of Rare Diseases is an initiative of the ISCIII. The authors acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), the Generalitat de Catalunya through the CERCA program and to the EMBL partnership.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Neurodevelopmental disorders: 2024 update

  • Martínez de Lagrán Cabredo, María
  • Bascón-Cardozo, Karen
  • Dierssen, Mara
Neurodevelopmental disorders encompass a range of conditions such as intellectual disability, autism spectrum disorder, rare genetic disorders and developmental and epileptic encephalopathies, all manifesting during childhood. Over 1,500 genes involved in various signaling pathways, including numerous transcriptional regulators, spliceosome elements, chromatin-modifying complexes and de novo variants have been recognized for their substantial role in these disorders. Along with new machine learning tools applied to neuroimaging, these discoveries facilitate genetic diagnoses, providing critical insights into neuropathological mechanisms and aiding in prognosis, and precision medicine. Also, new findings underscore the importance of understanding genetic contributions beyond protein-coding genes and emphasize the role of RNA and non-coding DNA molecules but also new players, such as transposable elements, whose dysregulation generates gene function disruption, epigenetic alteration, and genomic instability. Finally, recent developments in analyzing neuroimaging now offer the possibility of characterizing neuronal cytoarchitecture in vivo, presenting a viable alternative to traditional post-mortem studies. With a recently launched digital atlas of human fetal brain development, these new approaches will allow answering complex biological questions about fetal origins of cognitive function in childhood. In this review, we present ten fascinating topics where major progress has been made in the last year., The lab of M.D. acknowledges financial support from the Spanish Ministry of Science and Innovation (projects CPP2022-009659 and RTC2019-007329-1), the Spanish State Research Agency (project INTO-DS, reference PID2022-141900OB-I00), the Marato-TV3 Foundation (202212-30-31-32), and the European Comission Horizon 2020 programme (projects H2020-899986 and GO-DS21-848077). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Methods for identifying epilepsy surgery targets using invasive EEG: a systematic review

  • Ivankovic, Karla
  • Principe, Alessandro
  • Zucca, Riccardo
  • Dierssen, Mara
  • Rocamora Zúñiga, Rodrigo Alberto
Background: The pre-surgical evaluation for drug-resistant epilepsy achieves seizure freedom in only 50-60% of patients. Efforts to identify quantitative intracranial EEG (qEEG) biomarkers of epileptogenicity are needed. This review summarizes and evaluates the design of qEEG studies, discusses barriers to biomarker adoption, and proposes refinements of qEEG study protocols. Methods: We included exploratory and prediction prognostic studies from MEDLINE and Scopus published between 2017 and 2023 that investigated qEEG markers for identifying the epileptogenic network as the surgical target. Cohort parameters, ground truth references, and analytical approaches were extracted. Results: Out of 1789 search results, 128 studies were included. The study designs were highly heterogeneous. Half of the studies included a non-consecutive cohort, with sample sizes ranging from 2 to 166 patients (median of 16). The most common minimum follow-up was one year, and the seizure onset zone was the most common ground truth. Prediction studies were heterogeneous in their analytical approaches, and only 25 studies validated the marker through post-surgical outcome prediction. Outcome prediction performance decreased in larger cohorts. Conversely, longer follow-up periods correlated with higher prediction accuracy, and connectivity-based approaches yielded better predictions. The data and code were available in only 9% of studies. Conclusions: To enhance the validation qEEG markers, we propose standardizing study designs to resemble clinical trials. This includes using a consecutive cohort with long-term follow-up, validating against surgical resection as ground truth, and evaluating markers through post-surgical outcome prediction. These considerations would improve the reliability and clinical adoption of qEEG markers., K.I. is supported by Ajuts Destinats a Universitats, centres de recerca i fundacions hospitalàries per contractar personal investigador novell per a l'any 2022 (FI-DGR Grant Number: 14802). A.P. is supported by Fundación Tatiana-Proyectos en Neurociencia (Grant 2022-1514). R.Z. is supported by Neurotech-EU (Grant agreement ID: 101035817). M.D. is funded by the Agencia Estatal de Investigación (PID2022-141900OB-I00 INTO-DS), H2020 European Union's Horizon 2020 research and innovation programme under grant agreement No. 848077 and 899986, Jerôme Lejeune Foundation #2002. The APC was funded by Fundación Tatiana¿Proyectos en Neurociencia (Grant 20.22-15.14).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Modeling the impact of neuromorphological alterations in Down syndrome on fast neural oscillations

  • Clusella, Pau
  • Manubens-Gil, Linus, 1989-
  • García Ojalvo, Jordi
  • Dierssen, Mara
Cognitive disorders, including Down syndrome (DS), present significant morphological alterations in neuron architectural complexity. However, the relationship between neuromorphological alterations and impaired brain function is not fully understood. To address this gap, we propose a novel computational model that accounts for the observed cell deformations in DS. The model consists of a cross-sectional layer of the mouse motor cortex, composed of 3000 neurons. The network connectivity is obtained by accounting explicitly for two single-neuron morphological parameters: the mean dendritic tree radius and the spine density in excitatory pyramidal cells. We obtained these values by fitting reconstructed neuron data corresponding to three mouse models: wild-type (WT), transgenic (TgDyrk1A), and trisomic (Ts65Dn). Our findings reveal a dynamic interplay between pyramidal and fast-spiking interneurons leading to the emergence of gamma activity (∼40 Hz). In the DS models this gamma activity is diminished, corroborating experimental observations and validating our computational methodology. We further explore the impact of disrupted excitation-inhibition balance by mimicking the reduction recurrent inhibition present in DS. In this case, gamma power exhibits variable responses as a function of the external input to the network. Finally, we perform a numerical exploration of the morphological parameter space, unveiling the direct influence of each structural parameter on gamma frequency and power. Our research demonstrates a clear link between changes in morphology and the disruption of gamma oscillations in DS. This work underscores the potential of computational modeling to elucidate the relationship between neuron architecture and brain function, and ultimately improve our understanding of cognitive disorders., PC and JGO have received funding from the Future and Emerging Technologies Programme (FET) of the European Union’s Horizon 2020 research and innovation programme (project NEUROTWIN, grant agreement No 101017716). JGO was also financially supported by the Spanish Ministry of Science and Innovation (project reference PID2021-127311NB-I00), the FEDER funds of the Spanish State Research Agency (project reference MICIN/AEI/10.13039/501100011033/FEDER), the Maria de Maeztu Programme for Units of Excellence in R\&D of the Spanish State Research Agency (project reference CEX2018-000792-M), and by the ICREA Academia program. LMG was supported by the National Natural Science Foundation of China (RFIS-I grant, reference 32350410413). MD acknowledges financial support from the Spanish Ministry of Science and Innovation (projects CPP2022-009659 and RTC2019-007329-1), the Spanish State Research Agency (project INTO-DS, reference PID2022-141900OB-I00), the Marato-TV3 Foundation (202212-30-31-32), and the European Comission Horizon 2020 programme (projects H2020-899986 and GO-DS21-848077). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Understanding obesity in individuals with down syndrome: caregiver perceptions, awareness, and motivation

  • Cahill, Thomas
  • Nalesso, Valerie
  • Clarke, Pat
  • Martínez de Lagrán Cabredo, María
  • Strydom, Andre
  • Chan, Li
  • Potier, Marie-Claude
  • Beckers, Johannes
  • Langohr, Klaus
  • Liò, Pietro
  • Torre Fornell, Rafael de la
  • Forcano, Laura
  • Hiance-Delahaye, Anna
  • Herault, Yann
  • Dierssen, Mara
Background: Individuals with Down syndrome (DS) are at an increased risk of obesity and, subsequently, its cardiometabolic and cognitive impacts. Caregivers play a critical role in managing health, yet their perceptions and behaviors have been poorly characterized. Methods: We performed a cross-sectional online survey of caregivers (n = 764) taking care of 48% females and 52% males with DS, conducted across European populations, predominantly in Spain and France. We assessed perceived obesity, perceived harmfulness of current weight, professional consultation, and confidence in promoting healthy behaviors. Associations were examined using chi-square tests, correlation analysis, and ordinal and logistic regression models. Results: Around one-third (32%) of caregivers perceived their family member with DS with obesity. Perceived obesity changed with age and was more frequently reported in female family members with DS. Awareness of general metabolic risk factors was high among caregivers, but half of respondents were unaware that abdominal fat affects brain health. Consultation with healthcare professionals was uncommon (57% "Never/Rarely/Sometimes") even among those perceived with obesity. Conclusions: Caregivers demonstrate good general awareness about high energy food risks but limited knowledge of the link between obesity and brain health. Enhancing caregiver education and supporting behavioral change could promote healthier lifestyles in families with individuals with DS., This project received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 848077 (GO-DS21). The lab of M.D. and of RTF are recognized by the Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2023). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033), the Generalitat de Catalunya through the CERCA program and the EMBL partnership. KL received funding from PID2023-148033OB-C21 of the Ministerio de Ciencia, Innovación y Universidades (Spain; MICIU/AEI/10.13039/501100011033) and the European Regional development Fund (FEDER). LC received funding from Wellcome Trust grant (217543/Z/19/Z), and Barts Charity grant (G-002162). AS received funding from Medical Research Council grants (MR/S011277/1, MR/S005145/1, and MR/R024901/1) and the Jerome LeJeune Foundation. MD received funding from the Agencia Estatal de Investigación (PID2022-141900OB-I00 funded by MICIU/AEI/10.13039/501100011033/ERDF, EU), Fundació La Marató-TV3 (#202212-30), Ministerio de Ciencia Innovación y Universidades (RTC2019-007230-1, RTC2019-007329-1, and CPP2022-009659 funded by MCIN/AEI/10.13039/501100011033 and EU's 'NextGenerationEU'/PRTR'). The CIBER of Rare Diseases is an initiative of the ISCIII. RDT and LF research was supported by CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB06/03/0028), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A multimodal lifestyle intervention complemented with epigallocatechin gallate to prevent cognitive decline in APOE- e4 carriers with Subjective Cognitive Decline: a randomized, double-blinded clinical trial (PENSA study)

  • Forcano, Laura
  • Soldevila Domènech, Natàlia
  • Boronat Rigol, Anna
  • Sánchez Benavides, Gonzalo
  • Suárez Calvet, Marc
  • Cuenca, Aída
  • Domingo Gispert, Juan
  • Minguillón Gil, Carolina
  • Díaz Pellicer, Patricia
  • Fauria, Karine
  • Langohr, Klaus
  • Dierssen, Mara
  • Grau Rivera, Oriol
  • Molinuevo Guix, José Luis
  • De la Torre Fornell, Rafael
Background The potential of dietary compounds to enhance the effects of multimodal lifestyle interventions (MLIs) on cognition in individuals at high risk of cognitive impairment remains unclear. Objectives To assess whether the addition of a green tea extract enriched with epigallocatechin-3-gallate (EGCG) enhances the effects of an MLI. Design Double-blind, randomized, two-arm, and placebo-controlled trial. Exploratory comparisons were made with a non-randomized group (NRG) receiving healthy lifestyle recommendations. Setting: Population-based study conducted in Barcelona, Spain Participants APOE-¿4 carriers aged 60-80 with subjective cognitive decline Intervention A 12-month intensive MLI including dietary counseling, guided physical activity, and cognitive stimulation, combined with EGCG (5-6 mg/kg) or placebo, followed by a 3-month washout. Measurements Primary endpoint was change in the modified Preclinical Alzheimer Cognitive Composite (PACC-exe) score. Results 129 participants (65.1% 84 women, aged 66.7±5.5 years) were enrolled (52 MLI+EGCG, 52 MLI+placebo and 25 NRG), with126 (97.7%) included in the modified intention-to-treat analysis. After 12 months, no statistically significant difference was observed between MLI+EGCG and MLI+placebo in the PACC-exe (adjusted mean difference [AMD]: 0.12; 95%CI: -0.01, 0.24; p=0.061). However, participants in the MLI+EGCG group were 2.6 times more likely to show a reliable cognitive improvement. In exploratory analyses following a 3-month washout, the MLI+EGCG group showed significant cognitive benefits compared to the MLI+placebo (AMD: 0.19; 95%CI: 0.06, 0.32; p=0.005). Exploratory comparisons with the NRG also suggested greater gains in cognition and dementia risk reduction in both MLI groups, particularly with EGCG. Conclusions While the primary outcome was not met, this proof-of-concept trial suggests that combining MLIs with EGCG warrants further investigation in larger, confirmatory studies., This study was mainly funded by the Alzheimer’s Association, The PART THE CLOUD to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer’s disease Program, grant 18PTC-R-592192 and Project PI17/00223, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by European Regional Development Fund (FEDER). RdlT leads the Consolidated “Clinical Research Group in Pharmacology and Development of Biomarkers and New Drugs”, supported by the Generalitat de Catalunya (2021 SGR 00253 and 2021 SGR 01421). This research was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB06/03/0028), Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades (PID2022-141900OB-I00; PID2023-148033OB-C21) and Unión Europea – FEDER Fund; Grant AC22/00004 funded by Instituto de Salud Carlos III, and by the European Union NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MultiMemo, JPND program); and by the "Responsible Research and Innovation Awards" (RRI20/00005) organized by the ISCIII and promoted within the framework of the European project ORION (Open Responsible research and Innovation to further Outstanding kNowledge). NS-D had a predoctoral fellowship (2022 FI_B1 00026) from AGAUR-Generalitat de Catalunya, and TL had a predoctoral fellowship FI18/00041 from the ISCIII. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication, Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A multimodal lifestyle intervention complemented with epigallocatechin gallate to prevent cognitive decline in APOE- ɛ4 carriers with Subjective Cognitive Decline: a randomized, double-blinded clinical trial (PENSA study)

  • Forcano, Laura
  • Soldevila-Domenech, Natalia
  • Boronat Rigol, Anna, 1990-
  • Sánchez Benavides, Gonzalo
  • Puig-Pijoan, Albert
  • Lorenzo, Thais
  • Aldea-Perona, Ana
  • Suárez-Calvet, Marc
  • Cuenca Royo, Aida Ma, 1981-
  • Gispert López, Juan Domingo
  • Gomis González, Maria, 1988-
  • Minguillón, Carolina
  • Diaz-Pellicer, Patricia
  • Piera, Iris
  • Langohr, Klaus
  • Dierssen, Mara
  • Pizarro Lozano, Mª Nieves
  • Mur-Gimeno E.
  • Grau-Rivera, Oriol
  • Molinuevo, José Luis
  • Torre Fornell, Rafael de la
  • PENSA working group
Background: The potential of dietary compounds to enhance the effects of multimodal lifestyle interventions (MLIs) on cognition in individuals at high risk of cognitive impairment remains unclear. Objectives: To assess whether the addition of a green tea extract enriched with epigallocatechin-3-gallate (EGCG) enhances the effects of an MLI. Design: Double-blind, randomized, two-arm, and placebo-controlled trial. Exploratory comparisons were made with a non-randomized group (NRG) receiving healthy lifestyle recommendations. Setting: Population-based study conducted in Barcelona, Spain PARTICIPANTS: APOE-ɛ4 carriers aged 60-80 with subjective cognitive decline INTERVENTION: A 12-month intensive MLI including dietary counseling, guided physical activity, and cognitive stimulation, combined with EGCG (5-6 mg/kg) or placebo, followed by a 3-month washout. Measurements: Primary endpoint was change in the modified Preclinical Alzheimer Cognitive Composite (PACC-exe) score. Results: 129 participants (65.1% 84 women, aged 66.7±5.5 years) were enrolled (52 MLI+EGCG, 52 MLI+placebo and 25 NRG), with126 (97.7%) included in the modified intention-to-treat analysis. After 12 months, no statistically significant difference was observed between MLI+EGCG and MLI+placebo in the PACC-exe (adjusted mean difference [AMD]: 0.12; 95%CI: -0.01, 0.24; p=0.061). However, participants in the MLI+EGCG group were 2.6 times more likely to show a reliable cognitive improvement. In exploratory analyses following a 3-month washout, the MLI+EGCG group showed significant cognitive benefits compared to the MLI+placebo (AMD: 0.19; 95%CI: 0.06, 0.32; p=0.005). Exploratory comparisons with the NRG also suggested greater gains in cognition and dementia risk reduction in both MLI groups, particularly with EGCG. Conclusions: While the primary outcome was not met, this proof-of-concept trial suggests that combining MLIs with EGCG warrants further investigation in larger, confirmatory studies., This study was mainly funded by the Alzheimer¿s Association, The PART THE CLOUD to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer's disease Program, grant 18PTC-R-592192 and Project PI17/00223, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by European Regional Development Fund (FEDER). RdlT leads the Consolidated "Clinical Research Group in Pharmacology and Development of Biomarkers and New Drugs", supported by the Generalitat de Catalunya (2021 SGR 00253 and 2021 SGR 01421). This research was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB06/03/0028), Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades (PID2022-141900OB-I00; PID2023-148033OB-C21) and Unión Europea - FEDER Fund; Grant AC22/00004 funded by Instituto de Salud Carlos III, and by the European Union NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MultiMemo, JPND program); and by the "Responsible Research and Innovation Awards" (RRI20/00005) organized by the ISCIII and promoted within the framework of the European project ORION (Open Responsible research and Innovation to further Outstanding kNowledge). NS-D had a predoctoral fellowship (2022 FI_B1 00026) from AGAUR-Generalitat de Catalunya, and TL had a predoctoral fellowship FI18/00041 from the ISCIII. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication., This study was mainly funded by the Alzheimer’s Association, The PART THE CLOUD to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer’s disease Program, grant 18PTC-R-592192 and Project PI17/00223, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by European Regional Development Fund (FEDER). RdlT leads the Consolidated “Clinical Research Group in Pharmacology and Development of Biomarkers and New Drugs”, supported by the Generalitat de Catalunya (2021 SGR 00253 and 2021 SGR 01421). This research was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB06/03/0028), Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades (PID2022-141900OB-I00; PID2023-148033OB-C21) and Unión Europea – FEDER Fund; Grant AC22/00004 funded by Instituto de Salud Carlos III, and by the European Union NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MultiMemo, JPND program); and by the "Responsible Research and Innovation Awards" (RRI20/00005) organized by the ISCIII and promoted within the framework of the European project ORION (Open Responsible research and Innovation to further Outstanding kNowledge). NS-D had a predoctoral fellowship (2022 FI_B1 00026) from AGAUR-Generalitat de Catalunya, and TL had a predoctoral fellowship FI18/00041 from the ISCIII. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Astrocytopathy is associated with CA1 synaptic dysfunction in a mouse model of Down syndrome

  • Fernández-Blanco, Álvaro
  • González-Arias, Candela
  • Sierra, Cesar
  • Zamora Moratalla, Alfonsa
  • Perea, Gertrudis
  • Dierssen, Mara
Brain pathophysiology in Down syndrome (DS), the most common genetic cause of intellectual disability, has traditionally been considered a consequence of neuronal dysfunction. However, although it is well documented that astrocytes play a critical role in brain homeostasis, synaptic regulation, and neuronal support, and their malfunction has been associated with the onset and progression of different neurological disorders, only a few studies have addressed whether astrocyte dysfunction can contribute to the DS pathophysiology. Astrocytes are increased in number and size, and show increased levels of expression of astroglial markers like S100ß and GFAP. In this study, we detected a region-specific increase in astrocyte population in CA1 and, to a lesser extent, in the dentate gyrus. Single-nucleus transcriptomic profiling identified markers associated with reactive astroglia, synaptic transmission, and neuroinflammation in trisomic astrocytes. Functional analysis revealed abnormal Ca2+ oscillations in trisomic astrocytes and impaired astrocyte-to-neuron communication in CA1, the most affected subregion, leading to astrocyte-mediated excitatory synaptic depression. Our findings demonstrate that astrocytes play an active and critical role in the pathophysiology of DS, not only as reactive responders to neuronal injury but as key contributors to the disease process itself. This astrocytic dysfunction presents a region-specific distribution within the hippocampus, suggesting localized vulnerability and complex glial involvement in DS-related neuropathology., The lab of MD is supported by the Secretaria d¿Universitats i Recerca del Departament d'Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926). We also acknowledge the support of the Agencia Estatal de Investigación (PID2022-141900OB-I00 INTO-DS funded by MICIU/AEI/10.13039/501100011033/FEDER, UE). This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 848077). The publication is part of the grant PRE2018-084504, funded by MCIN/AEI/10.13039/501100011033 and by the FSE+ (AFB). Additionally, we have been supported by Fundació La Marató TV3 (201620-31 and 225619), and by PID2022-142617NB-I00 and PID2019-106579RB-I00 funded by MCIN/AEI/10.13039/501100011033 to G.P.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Factors influencing patient decision-making on a multimodal precision medicine algorithm for depression: a qualitative European multicentre study of the PROMPT consortium

  • Glaser, Rosa
  • Dierssen, Mara
  • Perera Bel, Júlia
  • Sanz, Ferran
  • Baune, Bernhard T.
Background: Precision medicine promises to improve treatment outcomes by tailoring interventions to patients' individual characteristics. However, the use of precision medicine tools requires patient acceptance, which remains underexplored. This qualitative study investigated factors influencing patient perspectives on a multimodal precision medicine algorithm to predict antidepressant response in patients suffering from Major Depressive Disorder (MDD). Methods: To explore patients' perspectives on the use of a multimodal algorithm, semi-structured focus groups were conducted with 44 patients diagnosed with moderate to severe depression across three European sites (Germany, Poland, Italy) in the PROMPT study. Discussions were transcribed and translated into English for analysis. A qualitative, structured content analysis approach was then used to analyse the data. Results: Patients' perspectives on using a multimodal algorithm in MDD revealed a complex interplay of decision-making factors: while perceived clinical benefits, such as a reduction in trial-and-error prescribing and reassurance, promoted acceptance of the algorithm, concerns about cost, waiting time and the emotional impact of unfavourable results tended to discourage acceptance. Patients' general beliefs about mental illness and its treatment shaped their attitudes toward the application of the algorithm. Many participants emphasised the importance of trust in physicians and preferred testing within the context of an established therapeutic relationship. Misconceptions about the algorithm's accuracy and capabilities, and fears of medical reductionism, were common. Conclusions: While patients are open to the use of a multimodal precision medicine algorithm for MDD, they emphasised the need for individualised, transparent communication and emotional support. The results highlight the importance of patient-centred communication strategies and guidelines for the ethical implementation of precision psychiatry., This study is part of the project "Toward PrecisiOn Medicine for the Prediction of Treatment response in major depressive disorder through stratification of combined clinical and -omics signatures", which is supported by the German Federal Ministry of Health (BMG) (2521FSB004_PROMPT), the National Centre for Research and Development Poland (NCBR) (PerMed/III/2/PROMPT/2021), the Italian Ministry of Health (IT-MoH) (ERP-2020-23671059), The French National Research Agency (ANR) (ANR-20-PERM-0003), the Health Department -Generalitat de Catalunya (DS-CAT) (SLD044/20/000001) and the Instituto de Salud Carlos III (ISCIII) (IHMC22/00026) under the frame of ERA PerMed. We acknowledge support of the Spanish Ministry of Science and Innovation (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033; PID2022-141900OB-I00), the Generalitat de Catalunya through the CERCA programme, the EMBL partnership and Fundació Marató TV3 (# 202212-30) to MD lab. MG and AM are supported by the Italian Ministry of Health (IT-MoH) under Grant Ricerca Corrente 2025 (RC-2025).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Attitudes towards a multimodal precision medicine algorithm for predicting treatment response in depression: findings from a large cross-sectional European survey

  • Wahner, Viktor T. H.
  • Dierssen, Mara
  • Perera Bel, Júlia
  • Sanz, Ferran
  • Baune, Bernhard T.
Background: Precision medicine aims to facilitate a more individualized treatment selection and a more accurate diagnosis. While there is broad ranging research on precision psychiatry and the corresponding computational tools, its concepts and implementation are underway, little is known about the attitudes towards the actual use of precision psychiatry tools in the management of major psychiatric disorders, such as Major Depressive Disorder (MDD). This study aims to investigate the attitudes of depressive patients, professionals (physicians, psychologists and scientists) and the general population towards a novel, multimodal precision medicine algorithm designed to predict antidepressant treatment response. Methods: 5490 participants from 21 European countries, consisting of three groups of stakeholders, patients with depression (n= 421), professionals (n = 367) and the general population (n = 4702), were polled with a newly developed cross-sectional survey. A hypothetical decision scenario was used to examine the participants' attitudes, in which they were asked for their approval or disapproval for the application of a multimodal precision medicine algorithm to predict treatment response in antidepressant-treatment.3. Results: The general population had an acceptance rate of 78.8%. Overall, 74.6% of patients with MDD would agree to undergo testing using the multimodal algorithm in their current situation and 80.2% reported they would have done so at the time of their first diagnosis. In contrast, the psychiatrist's acceptance rates towards a multimodal algorithm were higher when patients had been in treatment for some time (79.3%) compared to those who had only recently been diagnosed (55.2%). This pattern was present across all other specialties within the professionals group. A considerable number of participants wished to receive more information before deciding, but few declined its application altogether. All groups indicated an openness towards personalized treatment options in general. Conclusion: Overall, participants indicated a large degree of acceptance towards the application of a multimodal precision medicine algorithm. Although limited by the hypothetical nature of the decision scenario, this study provides valuable perspectives from different stakeholders. Future research should move beyond attitudes and address further implementation hurdles that need to be overcome for the successful implementation of novel precision psychiatry approaches in psychiatric care., This study is part of the project "Toward PrecisiOn Medicine for the Prediction of Treatment response in major depressive disorder through stratification of combined clinical and -omics signatures", which is supported by the German Federal Ministry of Health (BMG) (2521FSB004_PROMPT), the National Centre for Research and Development Poland (NCBR) (PerMed/III/2/PROMPT/2021), the Italian Ministry of Health (IT-MoH) (ERP-2020-23671059), The French National Research Agency (ANR) (ANR-20-PERM-0003), the Health Department -Generalitat de Catalunya (DS-CAT) (SLD044/20/000001) and the Instituto de Salud Carlos III (ISCIII) (IHMC22/00026) under the frame of ERA PerMed. We acknowledge support of the Spanish Ministry of Science and Innovation (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033; PID2022-141900OB-I00), the Generalitat de Catalunya through the CERCA programme, the EMBL partnership and Fundació Marató TV3 (# 202212-30) to MD lab. The assistant research position of Giulia Perusi is funded by ERA-PerMed PROMPT project (IT-MoH ERP-2020-23671059). The Ph.D. student position of Valentina Menesello was partly funded by the PNRR -DM 117/2023 Grant. Massimo Gennarelli and Alessandra Minelli are supported by the Italian Ministry of Health (IT-MoH) under Grant Ricerca Corrente 2025 (RC-2025).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Beyond quiescent and active: Intermediate microglial transcriptomic states in a mouse model of down syndrome

  • Fernández Blanco, Álvaro
  • Sierra, Cesar
  • Tejido, Clara
  • Dierssen, Mara
Research on microglia in Down syndrome (DS) has shown that microglial activation, increased inflammatory gene expression, and oxidative stress occur at different ages in DS brains. However, most studies resulted in simplistic definitions of microglia as quiescent or active, ignoring potential intermediate states. Indeed, recent work on microglial cells in young DS brains indicated that those evolve through different intermediate activation phenotypes before reaching a fully activated state. Here we used single nucleus RNA sequencing, to examine how trisomy affects microglial states in the Ts65Dn mouse model of DS. Despite no substantial changes in the proportion of glial populations, differential expression analysis revealed cell type-specific gene expression changes, most notably in astroglia, microglia, and oligodendroglia. Focusing on microglia, we identified differential expression of genes associated with different microglial states, including disease-associated microglia (DAMs), activated response microglia (ARMs), and human Alzheimer's disease microglia (HAMs), in trisomic microglia. Furthermore, pseudotime analysis reveals a unique reactivity profile in Ts65Dn microglia, with fewer in a homeostatic state and more in an intermediate aberrantly reactive state than in euploid microglia. This comprehensive understanding of microglial transcriptional dynamics sheds light on potential pathogenetic mechanisms but also possible avenues for therapy for neurodevelopmental disorders., The lab of MD is recognized by the Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2023). This project has received funding from the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033; PID2022-141900OB-I00 INTO-DS), from the European Union’s Horizon 2020 research and innovation program under grant agreement No 848077 and 899986, Jerôme Lejeune Foundation #2002, Fundació La Marató-TV3 (#2016/20-30), JPND Heroes Ministerio de Ciencia Innovación y Universidades (RTC2019-007230-1, RTC2019-007329-1; and CPP2022-009659). The CIBER of Rare Diseases is an initiative of the ISCIII. C.S. received the FI grant from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) de la Generalitat de Catalunya, and A.F.B. received an FPI-SO fellowship (PRE2018-084504).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Deficits in neuronal architecture but not over-inhibition are main determinants of reduced neuronal network activity in a mouse model of overexpression of Dyrk1A

  • Manubens-Gil, Linus|||0000-0003-2036-2204
  • Pons-Espinal, Meritxell|||0000-0003-0832-2963
  • Gener, Thomas|||0000-0001-9209-9228
  • Ballesteros-Yañez, Inmaculada|||0000-0003-4362-027X
  • Martínez de Lagrán, María|||0000-0002-0836-6491
  • Dierssen, Mara|||0000-0003-0853-6865
In this study, we investigated the impact of Dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) overexpression, a gene associated with Down syndrome, on hippocampal neuronal deficits in mice. Our findings revealed that mice overexpressing Dyrk1A (TgDyrk1A; TG) exhibited impaired hippocampal recognition memory, disrupted excitation-inhibition balance, and deficits in long-term potentiation (LTP). Specifically, we observed layer-specific deficits in dendritic arborization of TG CA1 pyramidal neurons in the stratum radiatum. Through computational modeling, we determined that these alterations resulted in reduced storage capacity and compromised integration of inputs, with decreased high γ oscillations. Contrary to prevailing assumptions, our model suggests that deficits in neuronal architecture, rather than over-inhibition, primarily contribute to the reduced network. We explored the potential of environmental enrichment (EE) as a therapeutic intervention and found that it normalized the excitation-inhibition balance, restored LTP, and improved short-term recognition memory. Interestingly, we observed transient significant dendritic remodeling, leading to recovered high γ. However, these effects were not sustained after EE discontinuation. Based on our findings, we conclude that Dyrk1A overexpression-induced layer-specific neuromorphological disturbances impair the encoding of place and temporal context. These findings contribute to our understanding of the underlying mechanisms of Dyrk1A-related hippocampal deficits and highlight the challenges associated with long-term therapeutic interventions for cognitive impairments.